MX2024000690A - Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas. - Google Patents

Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas.

Info

Publication number
MX2024000690A
MX2024000690A MX2024000690A MX2024000690A MX2024000690A MX 2024000690 A MX2024000690 A MX 2024000690A MX 2024000690 A MX2024000690 A MX 2024000690A MX 2024000690 A MX2024000690 A MX 2024000690A MX 2024000690 A MX2024000690 A MX 2024000690A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
antibody
same
provides
enoblituzumab
Prior art date
Application number
MX2024000690A
Other languages
English (en)
Spanish (es)
Inventor
Yan Zhou
Stephen James Burke
Krishnan Sampathkumar
Xiaoyan Wang
Original Assignee
Macrogenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrogenics Inc filed Critical Macrogenics Inc
Publication of MX2024000690A publication Critical patent/MX2024000690A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
MX2024000690A 2021-07-16 2022-07-06 Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas. MX2024000690A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163222750P 2021-07-16 2021-07-16
PCT/US2022/073462 WO2023288173A1 (en) 2021-07-16 2022-07-06 Pharmaceutical compositions of a b7-h3 antibody and use of the same

Publications (1)

Publication Number Publication Date
MX2024000690A true MX2024000690A (es) 2024-02-07

Family

ID=84920541

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024000690A MX2024000690A (es) 2021-07-16 2022-07-06 Composiciones farmaceuticas de un anticuerpo b7-h3 y uso de las mismas.

Country Status (11)

Country Link
US (1) US20240336687A1 (cg-RX-API-DMAC10.html)
EP (1) EP4370155A4 (cg-RX-API-DMAC10.html)
JP (1) JP2024526773A (cg-RX-API-DMAC10.html)
KR (1) KR20240038005A (cg-RX-API-DMAC10.html)
CN (1) CN117715657A (cg-RX-API-DMAC10.html)
AU (1) AU2022310668A1 (cg-RX-API-DMAC10.html)
CA (1) CA3224118A1 (cg-RX-API-DMAC10.html)
IL (1) IL310187A (cg-RX-API-DMAC10.html)
MX (1) MX2024000690A (cg-RX-API-DMAC10.html)
TW (1) TW202310874A (cg-RX-API-DMAC10.html)
WO (1) WO2023288173A1 (cg-RX-API-DMAC10.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR112012033457A2 (pt) * 2010-07-02 2017-04-04 Medimmune Llc formulações de anticorpo.
EP3714901A4 (en) * 2017-12-22 2022-03-02 Jiangsu Hengrui Medicine Co., Ltd. ANTI-LAG-3 ANTIBODY PHARMACEUTICAL COMPOSITION AND USE THEREOF
US20230041197A1 (en) * 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
JP7641908B2 (ja) * 2019-03-29 2025-03-07 ジエンス ヘンルイ メデイシンカンパニー リミテッド Il-5に対する抗体を含有する医薬組成物及びその使用
KR20220119694A (ko) * 2019-12-23 2022-08-30 마크로제닉스, 인크. 암 치료를 위한 요법
CN115103691B (zh) * 2020-03-25 2025-01-24 苏州盛迪亚生物医药有限公司 一种含抗体药物偶联物的药物组合物及其用途

Also Published As

Publication number Publication date
EP4370155A4 (en) 2025-06-11
WO2023288173A1 (en) 2023-01-19
AU2022310668A1 (en) 2024-01-18
CA3224118A1 (en) 2023-01-19
KR20240038005A (ko) 2024-03-22
US20240336687A1 (en) 2024-10-10
CN117715657A (zh) 2024-03-15
IL310187A (en) 2024-03-01
EP4370155A1 (en) 2024-05-22
TW202310874A (zh) 2023-03-16
JP2024526773A (ja) 2024-07-19

Similar Documents

Publication Publication Date Title
EP4685160A3 (en) Combination therapy including a krasg12c inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CR20220614A (es) 2-amino-3-cianotiofenos anulados y derivados para el tratamiento del cáncer
Shekarian et al. Paradigm shift in oncology: targeting the immune system rather than cancer cells
Khan et al. Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer
SA521430342B1 (ar) تركيبة سائلة تشتمل على جسم مضاد لمستقبل ألفا إنترليوكين -4 البشري
MX2023009971A (es) Composicion farmaceutica que contiene anticuerpo anti-tslp.
WO2019136300A3 (en) Anti-mct1 antibodies and uses thereof
McMillan et al. Antibody-drug conjugates for multiple myeloma
Rasche et al. Novel immunotherapies in multiple myeloma–chances and challenges
PH12020500205A1 (en) Anti-cd147 antibody
Parrondo et al. Bispecific antibodies for the treatment of relapsed/refractory multiple myeloma: updates and future perspectives
MX2024014070A (es) Composicion farmaceutica que contiene un conjugado de anticuerpo anti-nectina-4 y uso del mismo
MX2023004533A (es) Formulaciones de anticuerpos anti-siglec-8.
Van de Donk et al. S183: novel combination immunotherapy for the treatment of relapsed/refractory multiple myeloma: updated phase 1B results for talquetamab (a GPRC5D X CD3 bispecific antibody) in combination with daratumumab
WO2022047047A8 (en) Inhalable therapeutic agents
MX2025005092A (es) Anticuerpo anti-trem2 y usos del mismo
WO2022022464A8 (zh) 新型双特异性抗cd3/cd20多肽复合物配制剂
Hosen Chimeric antigen receptor T-cell therapy for multiple myeloma
MX2026000276A (es) Composiciones y metodos para tratar la esclerosis multiple
EP4245374A3 (en) Pvrl2 and/or pvrig as biomarkers for treatment
van de Donk et al. P07: results from the CC-220-MM-001 dose-expansion phase of iberdomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
Polito et al. ATG‐saporin‐S6 immunotoxin: a new potent and selective drug to eliminate activated lymphocytes and lymphoma cells
CR20240065A (es) Composiciones farmacéuticas de un anticuerpo contra pd-1 y uso de las mismas
WO2020176748A8 (en) Dosing for treatment with anti-tigit and anti-cd20 or anti-cd38 antibodies
Higano New treatment options for patients with metastatic castration-resistant prostate cancer